Background The ongoing coronavirus disease 2019 (COVID-2019) pandemic has swept all
over the world, posing a great pressure on critical care resources due to large number of …

Background The effect of corticosteroids on clinical outcomes in patients with influenza
pneumonia remains controversial. We aimed to further evaluate the influence of …

These clinical practice guidelines are an update of the guidelines published by the
Infectious Diseases Society of America (IDSA) in 2009, prior to the 2009 H1N1 influenza …

Rationale: Corticosteroid therapy is commonly used among critically ill patients with Middle
East Respiratory Syndrome (MERS), but its impact on outcomes is uncertain. Analyses of …

Individuals suffering from severe viral respiratory tract infections have recently emerged as
“at risk” groups for developing invasive fungal infections. Influenza virus is one of the most …

BACKGROUND: Very little direct evidence exists on use of corticosteroids in patients with
coronavirus disease 2019 (COVID-19). Indirect evidence from related conditions must …

Background The aim of this study was to estimate the prevalence of pneumonia and
secondary bacterial infections during the pandemic of influenza A (H1N1) pdm09. Methods …

Background: There is still no clinical evidence available to support or to oppose
corticosteroid treatment for coronavirus disease 2019 (COVID-19) pneumonia. Objective: To …

The first edition of this document was published in 2013 and was revised in 2015. The
current version is aligned with other WHO documents on case definitions and laboratory …

Background A synergistic effect of combination therapy with favipiravir and oseltamivir has
been reported in preclinical models of influenza. However, no data are available on the …